New Oral Pill Cuts Bad Cholesterol by 60% in Major Clinical Trial

A groundbreaking oral medication called enlicitide has demonstrated the ability to reduce LDL cholesterol by 60% in a phase three clinical trial, potentially revolutionizing cardiovascular disease prevention. This matters because LDL cholesterol buildup in arteries causes heart attacks and strokes, yet current powerful treatments require injections that many patients and doctors avoid.

The trial, led by UT Southwestern researchers and published in The New England Journal of Medicine, showed enlicitide matches the effectiveness of existing injectable PCSK9 inhibitors while offering the convenience of a daily pill. The drug works by targeting the PCSK9 protein, which normally limits the liver's ability to clear cholesterol from the bloodstream.

This research builds on Nobel Prize-winning discoveries about cholesterol metabolism and genetic studies showing some people naturally produce less PCSK9 protein, resulting in lower cholesterol levels. Current injectable treatments like evolocumab achieve similar 60% reductions but remain underused despite improved insurance coverage.

For health optimization, this could be transformative since fewer than half of people with established heart disease currently reach safe cholesterol targets, even with statins. An oral option could dramatically expand access to powerful cholesterol reduction, potentially preventing countless heart attacks and strokes on a population level.

However, the drug still requires FDA approval, and long-term safety data remains limited. The study was sponsored by Merck, requiring consideration of potential bias. While promising, patients should continue current treatments and consult healthcare providers about future options.